You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
McKinsey
AstraZeneca
Harvard Business School

Last Updated: October 22, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,579,981

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,579,981 protect, and when does it expire?

Patent 6,579,981 protects DENAVIR and is included in one NDA.

This patent has seventy-one patent family members in twenty-seven countries.

Summary for Patent: 6,579,981
Title: Antiviral guanine derivatives
Abstract:A compound of formula (I) ##STR1## or a salt or acyl derivative thereof, in which X represents chlorine, C.sub.1-6 alkoxy, phenoxy, phenyl C.sub.1-6 alkoxy, NH.sub.2, --OH or --SH, is useful in treating viral infections.
Inventor(s): Jarvest; Richard Lewis (Surbiton, GB), Harnden; Michael Raymond (Horsham, GB)
Assignee: Novartis International Pharmaceutical Ltd. (Hamilton, BM)
Application Number:08/311,291
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation;

Drugs Protected by US Patent 6,579,981

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 RX Yes Yes   Start Trial   Start Trial TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,579,981

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8325271Sep 21, 1908
United Kingdom8322199Aug 18, 1983
United Kingdom8408322Mar 30, 1984

International Family Members for US Patent 6,579,981

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 389118   Start Trial
Austria A904286   Start Trial
Australia 3197384   Start Trial
Australia 4756085   Start Trial
Australia 577303   Start Trial
Australia 589371   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Merck
Medtronic
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.